BASIS (Breast Cancer Somatic Genetics Study)
Withdrawn
- Conditions
- breastcancer1000629110006295
- Registration Number
- NL-OMON37355
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Withdrawn
- Sex
- Not specified
- Target Recruitment
- 500
Inclusion Criteria
The tumorsubtype is ER+ HER2-
Tumor has to be removed surgically
Exclusion Criteria
Tumor has been treated with preoperative radiation and/or chemotherapy
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Full genome DNA sequencing and RNA expression profiling. Potential cancer genes<br /><br>will be further analyzed by using in situ hybridization and RT-PCR.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Full genome methylation analysis will be performed.<br /><br>mRNA en miRNA expression profiling</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What somatic mutations in breast cancer are linked to resistance to endocrine therapy in the BASIS study (NL-OMON37355)?
How does genetic profiling in NL-OMON37355 compare to standard-of-care treatment outcomes in HER2-negative breast cancer?
Which biomarkers in the BASIS trial (NL-OMON37355) predict response to PARP inhibitors in BRCA-mutated breast cancer patients?
What adverse events are associated with targeted therapies identified in the Academisch Medisch Centrum's breast cancer somatic genetics study?
Are there combination therapies involving CDK4/6 inhibitors and genetic markers from the BASIS (NL-OMON37355) trial showing improved survival in metastatic breast cancer?